RICARDO OSORIO: Open Payments
NPI 1093272668 · SIOUX CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,175 in 147 payments from 11 companies in 2025. Trend: 2023 $1,363 · 2024 $2,140 · 2025 $2,175
Food & beverage: $2,175
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 21 | $422 |
| ABBVIE INC. | 28 | $365 |
| Otsuka America Pharmaceutical, Inc. | 19 | $297 |
| Neurocrine BioSciences, Inc. | 17 | $228 |
| E.R. Squibb & Sons, L.L.C. | 16 | $209 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $190 |
| Vanda Pharmaceuticals Inc. | 14 | $178 |
| Teva Pharmaceuticals USA, Inc. | 7 | $120 |
| Corium, LLC | 6 | $84 |
| Insulet Corporation | 1 | $45 |
Products named: VRAYLAR, ARISTADA, INGREZZA, REXULTI, COBENFY, CAPLYTA, LYBALVI, HETLIOZ.
Industry payments across IA — which companies pay providers there.
